MedTrace Logo

A Phase 2b Randomised, Placebo Controlled Study of OligoG in Patients with Cystic Fibrosis

NCT03822455 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-10-28

No results posted yet for this study

Summary

A double-blind, randomised study of OligoG DPI compared to placebo DPI, both on top of standard-of-care, to assess safety, efficacy and tolerability. Adult patients with Cystic Fibrosis will be included in the study.

Conditions

Interventions

DRUG

OligoG DPI

OligoG Dry Powder for Inhalation

Sponsors & Collaborators

  • AlgiPharma AS

    lead INDUSTRY

Principal Investigators

  • Peter Wark · John Hunter Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-16
Primary Completion
2020-03-11
Completion
2021-07-10

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03822455 on ClinicalTrials.gov